Top Markets
#1 Wrapped STX (Velar) Wrapped STX (Velar) +37.02%
#2 Siren Siren +30.70%
#3 Purr Purr +26.40%
#4 ApeX ApeX +17.01%
#5 UnifAI Network UnifAI Network +16.45%
#6 OriginTrail OriginTrail +15.97%
#7 Pendle Pendle +15.57%
#8 Morpho Morpho +14.85%
#9 Zora Zora +14.60%
#10 龙虾 (Lobster) 龙虾 (Lobster) +14.25%
Coin of the day
Wrapped STX (Velar) Wrapped STX (Velar)
Settings
Language
ENGLISH
Currency
USD
Theme
Genovate Biotechnology Co., Ltd. Genovate Biotechnology Co., Ltd.

Genovate Biotechnology Co., Ltd.

4130
Rank in Stocks #21465
Genovate Biotechnology Co., Ltd. is a Taiwanese enterprise dedicated to the... Genovate Biotechnology Co., Ltd. is a Taiwanese enterprise dedicated to the research, development, production, and commercialization of various products. These offerings primarily aim to prevent and treat illnesses resulting from viral and bacterial infections. The company's diverse portfolio extends to drugs, active pharmaceutical ingredients (APIs), intermediates, and specialized release agents, which are crucial for addressing a range of health issues including cardiovascular, esophageal, gastrointestinal, cancer, and autoimmune conditions. Complementing its pharmaceutical offerings, Genovate also manufactures controlled-release Western medicine formulations and cosmetic items. Established in 1982, the company's operations are headquartered in Hsinchu City, Taiwan.
Share Price
$0.84903405
Last synced: 2026-07-27
Market Cap
$106.63M
Change (1 day)
0.00%
Change (1 year)
38.69%
Country
TW
Trade Genovate Biotechnology Co., Ltd. (4130)

Category

Healthcare
Revenue for Genovate Biotechnology Co., Ltd. (4130)
Revenue in Aug 2026 TTM: 0
According to Genovate Biotechnology Co., Ltd. latest financial reports the company's current revenue (TTM) is 0. In 2026 the company made a revenue of 0 equal to the revenue in the year 2026 that was 0. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Genovate Biotechnology Co., Ltd. from 2026 to 2026
Revenue at the end of each year
Year Revenue Change
Not enough data for the provided dates.
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.62B -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $6.02B -
NL
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
 $2.23B -
US
CSL Limited CSL Limited
CSL Limited
CSL.AX
 $15.74B -
AU
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH